Beyond calcineurin inhibitors: emerging agents in kidney transplantation

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Current opinion in nephrology and hypertension

• Publication date

  2013-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MNH.0b013e328365b3e6PMID 24100221
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• JAKs and STATs in immunity, immunodeficiency, and cancer.

  2013cited by this paper
• Calcineurin inhibition and new-onset diabetes mellitus after transplantation.

  2013cited by this paper
• Sotrastaurin in Calcineurin Inhibitor–Free Regimen Using Everolimus in De Novo Kidney Transplant Recipients

  2013cited by this paper
• Everolimus-Treated Renal Transplant Recipients Have a More Robust CMV-Specific CD8+ T-Cell Response Compared With Cyclosporine- or Mycophenolate-Treated Patients

  2013cited by this paper
• Belatacept and Sirolimus Prolong Nonhuman Primate Islet Allograft Survival: Adverse Consequences of Concomitant Alefacept Therapy

  2013cited by this paper
• Belatacept and Sirolimus Prolong Nonhuman Primate Renal Allograft Survival Without a Requirement for Memory T Cell Depletion

  2013cited by this paper
• Alefacept Combined With Tacrolimus, Mycophenolate Mofetil and Steroids in De Novo Kidney Transplantation: A Randomized Controlled Trial

  2013cited by this paper
• Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer

  2012cited by this paper
• Belatacept for prevention of acute rejection in adult patients who have had a kidney transplant: an update

  2012cited by this paper
• Faculty Opinions recommendation of Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.

  2012cited by this paper
• Fatal PML associated with efalizumab therapy

  2012cited by this paper
• Sirolimus and secondary skin-cancer prevention in kidney transplantation.

  2012cited by this paper
• Randomized Phase 2b Trial of Tofacitinib (CP‐690,550) in De Novo Kidney Transplant Patients: Efficacy, Renal Function and Safety at 1 Year

  2012cited by this paper
• CD28‐Specific Immunomodulating Antibodies: What Can Be Learned From Experimental Models?

  2012cited by this paper
• Enhanced De Novo Alloantibody and Antibody‐Mediated Injury in Rhesus Macaques

  2012cited by this paper
• A Novel Monoclonal Antibody to CD40 Prolongs Islet Allograft Survival

  2012cited by this paper
• The Role of Costimulatory Molecules in Directing the Functional Differentiation of Alloreactive T Helper Cells

  2012cited by this paper
• Deleterious Effect of CTLA4‐Ig on a Treg‐Dependent Transplant Model

  2012cited by this paper
• Sotrastaurin (AEB071) Alone and in Combination With Cyclosporine A Prolongs Survival Times of Non-Human Primate Recipients of Life-Supporting Kidney Allografts

  2012cited by this paper
• Are calcineurin inhibitors-free regimens ready for prime time?

  2012cited by this paper
• Nondepleting Anti‐CD40‐Based Therapy Prolongs Allograft Survival in Nonhuman Primates

  2012cited by this paper
• Combined Costimulatory and Leukocyte Functional Antigen-1 Blockade Prevents Transplant Rejection Mediated by Heterologous Immune Memory Alloresponses

  2012cited by this paper
• Sotrastaurin, a new selective protein kinase C inhibitor, on the way.

  2012cited by this paper
• Therapeutics: Silencing psoriasis

  2012influential reference
• Three‐Year Outcomes From BENEFIT‐EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

  2012cited by this paper
• Summary of the US FDA Approval of Belatacept

  2012cited by this paper
• Sotrastaurin single‐dose pharmacokinetics in de novo liver transplant recipients

  2011cited by this paper
• Sotrastaurin, a Novel Small Molecule Inhibiting Protein‐Kinase C: Randomized Phase II Study in Renal Transplant Recipients

  2011cited by this paper
• m-TOR inhibitors: what role in liver transplantation?

  2011cited by this paper
• Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.

  2011cited by this paper
• CD40‐Specific Costimulation Blockade Enhances Neonatal Porcine Islet Survival in Nonhuman Primates

  2011cited by this paper
• Islet Transplantation in Type 1 Diabetic Patients Using Calcineurin Inhibitor-Free Immunosuppressive Protocols Based on T-Cell Adhesion or Costimulation Blockade

  2010cited by this paper
• Advances in immunosuppression for renal transplantation

  2010cited by this paper
• Five-year safety and efficacy of belatacept in renal transplantation.

  2010cited by this paper
• A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

  2010cited by this paper
• Sotrastaurin, a Novel Small Molecule Inhibiting Protein Kinase C: First Clinical Results in Renal‐Transplant Recipients

  2010cited by this paper
• A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)

  2010cited by this paper
• Anti-BK Virus Mechanisms of Sirolimus and Leflunomide Alone and in Combination: Toward a New Therapy for BK Virus Infection

  2010cited by this paper
• Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720

  2010cited by this paper
• Everolimus Plus Reduced‐Exposure CsA versus Mycophenolic Acid Plus Standard‐Exposure CsA in Renal‐Transplant Recipients

  2010cited by this paper
• Management of Side Effects of Sirolimus Therapy

  2009cited by this paper
• ALEFACEPT PROMOTES COSTIMULATION BLOCKADE BASED ALLOGRAFT SURVIVAL IN PRIMATES

  2009cited by this paper
• CD28 superagonists: what makes the difference in humans?

  2008cited by this paper
• Two cases of calcineurin inhibitor-associated reversible posterior leukoencephalopathy syndrome in renal transplant recipients.

  2008cited by this paper
• The PKC inhibitor AEB071 may be a therapeutic option for psoriasis.

  2008cited by this paper
• Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies.

  2007cited by this paper
• A Phase I/II Randomized Open‐Label Multicenter Trial of Efalizumab, a Humanized Anti‐CD11a, Anti‐LFA‐1 in Renal Transplantation

  2007influential reference
• LFA‐1 (CD11a) as a Therapeutic Target

  2006cited by this paper
• CTLA4Ig: bridging the basic immunology with clinical application.

  2006cited by this paper
• Primer: histopathology of calcineurin-inhibitor toxicity in renal allografts

  2006cited by this paper
• Hyperuricemia and gout following pediatric renal transplantation

  2006cited by this paper
• New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?

  2006cited by this paper
• Three‐Year Efficacy and Safety Results from a Study of Everolimus Versus Mycophenolate Mofetil in de novo Renal Transplant Patients

  2005cited by this paper
• Tacrolimus-Induced Alopecia in Female Kidney-Pancreas Transplant Recipients

  2005cited by this paper
• Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties

  2005cited by this paper
• Costimulation blockade with belatacept in renal transplantation.

  2005cited by this paper
• Costimulation blockade with belatacept in renal transplantation.

  2005cited by this paper
• Everolimus versus Mycophenolate Mofetil in the Prevention of Rejection in De Novo Renal Transplant Recipients: A 3-Year Randomized, Multicenter, Phase III Study

  2005cited by this paper
• Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients

  2004cited by this paper
• Cyclosporine nephrotoxicity.

  2004cited by this paper
• Sirolimus: its discovery, biological properties, and mechanism of action.

  2003cited by this paper
• Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor

  2003cited by this paper
• Drug-Induced Thrombotic Microangiopathy

  2001cited by this paper
• Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

  2001cited by this paper
• Neurotoxicity of calcineurin inhibitors: impact and clinical management

  2000cited by this paper
• Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group.

  2000cited by this paper
• Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand

  2000cited by this paper
• CTLA4-Ig: a novel immunosuppressive agent

  2000cited by this paper
• Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

  2000cited by this paper
• Sirolimus and ciclosporin for renal transplantation

  2000cited by this paper
• Sirolimus and cyclosporin for renal transplantation.

  2000cited by this paper
• Cyclosporine nephrotoxicity.

  1985cited by this paper
• Side Effects of Systemic Cyclosporine in Patients Not Undergoing Transplantation

  1985cited by this paper
• Side effects of systemic cyclosporine in patients not undergoing transplantation.

  1984cited by this paper

• Overexpression of PD-1 on T cells promotes tolerance in cardiac transplantation via ICOS-dependent mechanisms

  2021cites this paper
• Stable and destabilized GFP reporters to monitor calcineurin activity in Saccharomyces cerevisiae

  2020cites this paper
• Chronic allograft injury: Mechanisms and potential treatment targets.

  2017cites this paper
• Design, synthesis, and evaluation of 4,6-diaminonicotinamide derivatives as novel and potent immunomodulators targeting JAK3.

  2016cites this paper
• Calcineurin Targets Involved in Stress Survival and Fungal Virulence

  2016cites this paper
• Profile of the Pleximmune blood test for transplant rejection risk prediction

  2016cites this paper
• Pharmacologic Targeting of Regulatory T Cells for Solid Organ Transplantation: Current and Future Prospects

  2015cites this paper
• Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting Janus kinase 3.

  2015cites this paper
• The Neurology of Solid Organ Transplantation

  2015cites this paper
• Erratum to: Pharmacologic Targeting of Regulatory T Cells for Solid Organ Transplantation: Current and Future Prospects

  2015cites this paper
• Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.

  2015cites this paper
• Inhibition von Signalkaskaden in der immunsuppressiven Therapie nach Nierentransplantation

  2014cites this paper
• The calcineurin signaling network evolves via conserved kinase-phosphatase modules that transcend substrate identity.

  2014cites this paper
• Preliminary Report of Major Surgery in Liver Transplant Recipients Receiving m-TOR Inhibitors without Therapeutic Discontinuation

  2014cites this paper
• The calcineurin signaling network evolves via conserved kinase‐phosphatase modules that transcend substrate identity (586.3)

  2014cites this paper